ARTEMIS 011 Improves Osteosarcoma Progression Control
Hansoh disclosed full Phase III ARTEMIS-011 results on 27 October, following the 26 October ESMO presentation. In heavily pretreated relapsed osteosarcoma in China, the B7-H3 ADC risvutatug rezetecan improved central-review PFS against gemcitabine–docetaxel. Safety…
